Systematic evaluation of Tongxinluo Capsule combined with atorvastatin in treatment of carotid atherosclerosis
Objective Systematic evaluation of the efficacy and safety of Tongxinluo Capsule combined with atorvastatin in the treatment of carotid atherosclerosis.Methods A comprehensive screening of Tongxinluo Capsule combined with atorvastatin was performed by web searching the CNKI,Wanfang Data,VIP,PubMed,Embase,Cochrane Library,and Web of Science from the construction of the database to August 31,2023,to comprehensively screen the literature of randomized controlled studies of Tongxinluo Capsule combined with atorvastatin in the treatment of carotid atherosclerosis in the literature of randomized controlled studies,and Meta-analysis was performed using RevMan 5.4 software.Results A total of 16 RCTs were included with 1 654 total cases,832 in the treatment group and 822 in the control group.Meta-analysis showed that the addition of Tongxinluo Capsule to atorvastatin treatment lowered total cholesterol(TC)[MD ＝-0.62,95％CI(-0.87,-0.37),P＜0.000 01],triglycerides(TG)[MD=-0.28,95％CI(-0.41,-0.15),P＜0.000 1],low-density lipoprotein cholesterol(LDL-C)[MD=-0.38,95％CI(-0.56,-0.20),P＜0.000 1]and increased high-density lipoprotein cholesterol(HDL-C)levels[MD=0.22,95％ CI(0.06,0.38),P=0.008],lowered carotid intima-media thickness(IMT)[MD=-0.21,95％ CI(-0.27,-0.15),P＜0.000 01]and plaque Crouse's score[MD=-1.05,95％CI(-1.29,-0.80),P＜0.000 01],and lowered high-sensitivity C-reactive protein(hs-CRP)[MD=-0.44,95％ CI(-0.57,-0.31),P＜0.000 01]and interleukin-6(IL-6)levels[MD=-3.96,95％ CI(-6.25,-1.66),P=0.000 7],and the differences were statistically significant(P＜0.05).Adverse reactions were reported in seven studies,and a comparison of the incidence of adverse reactions[OR=1.48,95％CI(0.78,2.82),P=0.23]showed no statistically significant difference.Conclusion Tongxinluo Capsule combined with atorvastatin in the treatment of carotid atherosclerosis can improve the blood lipid level and inflammatory response,reduce the degree of atherosclerosis,with better efficacy and safety,and is recommended to be further promoted for clinical use.
NETL
NSTL
万方数据
